Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts

Gaspar J. Kitange, Brett L. Carlson, Mark A. Schroeder, Patrick T. Grogan, Jeff D. Lamont, Paul A. Decker, Wenting Wu, C. David James, Jann N Sarkaria

Research output: Contribution to journalArticle

117 Citations (Scopus)

Abstract

Temozolomide (TMZ)-based therapy is the standard of care for patients with glioblastoma multiforme (GBM), and resistance to this drug in GBM is modulated by the DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT). Expression of MGMT is silenced by promoter methylation in approximately half of GBM tumors, and clinical studies have shown that elevated MGMT protein levels or lack of MGMT promoter methylation is associated with TMZ resistance in some, but not all, GBM tumors. In this study, the relationship between MGMT protein expression and tumor response to TMZ was evaluated in four GBM xenograft lines that had been established from patient specimens and maintained by serial subcutaneous passaging in nude mice. Three MGMT unmethylated tumors displayed elevated basal MGMT protein expression, but only two of these were resistant to TMZ therapy (tumors GBM43 and GBM44), while the other (GBM14) displayed a level of TMZ sensitivity that was similar in extent to that seen in a single MGMT hypermethylated line (GBM12). In tissue culture and animal studies, TMZ treatment resulted in robust and prolonged induction of MGMT expression in the resistant GBM43 and GBM44 xenograft lines, while MGMT induction was blunted and abbreviated in GBM14. Consistent with a functional significance of MGMT induction, treatment of GBM43 with a protracted low-dose TMZ regimen was significantly less effective than a shorter high-dose regimen, while survival for GBM14 was improved with the protracted dosing regimen. In conclusion, MGMT expression is dynamically regulated in some MGMT nonmethylated tumors, and in these tumors, protracted dosing regimens may not be effective.

Original languageEnglish (US)
Pages (from-to)281-291
Number of pages11
JournalNeuro-Oncology
Volume11
Issue number3
DOIs
StatePublished - Jun 2009

Fingerprint

temozolomide
Methyltransferases
Glioblastoma
Heterografts
DNA
Protein Methyltransferases
Neoplasms
Methylation

Keywords

  • Glioblastoma xenografts
  • MGMT induction
  • Promoter methylation
  • Temozolomide

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Clinical Neurology

Cite this

Kitange, G. J., Carlson, B. L., Schroeder, M. A., Grogan, P. T., Lamont, J. D., Decker, P. A., ... Sarkaria, J. N. (2009). Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro-Oncology, 11(3), 281-291. https://doi.org/10.1215/15228517-2008-090

Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. / Kitange, Gaspar J.; Carlson, Brett L.; Schroeder, Mark A.; Grogan, Patrick T.; Lamont, Jeff D.; Decker, Paul A.; Wu, Wenting; James, C. David; Sarkaria, Jann N.

In: Neuro-Oncology, Vol. 11, No. 3, 06.2009, p. 281-291.

Research output: Contribution to journalArticle

Kitange, GJ, Carlson, BL, Schroeder, MA, Grogan, PT, Lamont, JD, Decker, PA, Wu, W, James, CD & Sarkaria, JN 2009, 'Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts', Neuro-Oncology, vol. 11, no. 3, pp. 281-291. https://doi.org/10.1215/15228517-2008-090
Kitange GJ, Carlson BL, Schroeder MA, Grogan PT, Lamont JD, Decker PA et al. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro-Oncology. 2009 Jun;11(3):281-291. https://doi.org/10.1215/15228517-2008-090
Kitange, Gaspar J. ; Carlson, Brett L. ; Schroeder, Mark A. ; Grogan, Patrick T. ; Lamont, Jeff D. ; Decker, Paul A. ; Wu, Wenting ; James, C. David ; Sarkaria, Jann N. / Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. In: Neuro-Oncology. 2009 ; Vol. 11, No. 3. pp. 281-291.
@article{57737881cd5944caba8bc2342e16e747,
title = "Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts",
abstract = "Temozolomide (TMZ)-based therapy is the standard of care for patients with glioblastoma multiforme (GBM), and resistance to this drug in GBM is modulated by the DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT). Expression of MGMT is silenced by promoter methylation in approximately half of GBM tumors, and clinical studies have shown that elevated MGMT protein levels or lack of MGMT promoter methylation is associated with TMZ resistance in some, but not all, GBM tumors. In this study, the relationship between MGMT protein expression and tumor response to TMZ was evaluated in four GBM xenograft lines that had been established from patient specimens and maintained by serial subcutaneous passaging in nude mice. Three MGMT unmethylated tumors displayed elevated basal MGMT protein expression, but only two of these were resistant to TMZ therapy (tumors GBM43 and GBM44), while the other (GBM14) displayed a level of TMZ sensitivity that was similar in extent to that seen in a single MGMT hypermethylated line (GBM12). In tissue culture and animal studies, TMZ treatment resulted in robust and prolonged induction of MGMT expression in the resistant GBM43 and GBM44 xenograft lines, while MGMT induction was blunted and abbreviated in GBM14. Consistent with a functional significance of MGMT induction, treatment of GBM43 with a protracted low-dose TMZ regimen was significantly less effective than a shorter high-dose regimen, while survival for GBM14 was improved with the protracted dosing regimen. In conclusion, MGMT expression is dynamically regulated in some MGMT nonmethylated tumors, and in these tumors, protracted dosing regimens may not be effective.",
keywords = "Glioblastoma xenografts, MGMT induction, Promoter methylation, Temozolomide",
author = "Kitange, {Gaspar J.} and Carlson, {Brett L.} and Schroeder, {Mark A.} and Grogan, {Patrick T.} and Lamont, {Jeff D.} and Decker, {Paul A.} and Wenting Wu and James, {C. David} and Sarkaria, {Jann N}",
year = "2009",
month = "6",
doi = "10.1215/15228517-2008-090",
language = "English (US)",
volume = "11",
pages = "281--291",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts

AU - Kitange, Gaspar J.

AU - Carlson, Brett L.

AU - Schroeder, Mark A.

AU - Grogan, Patrick T.

AU - Lamont, Jeff D.

AU - Decker, Paul A.

AU - Wu, Wenting

AU - James, C. David

AU - Sarkaria, Jann N

PY - 2009/6

Y1 - 2009/6

N2 - Temozolomide (TMZ)-based therapy is the standard of care for patients with glioblastoma multiforme (GBM), and resistance to this drug in GBM is modulated by the DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT). Expression of MGMT is silenced by promoter methylation in approximately half of GBM tumors, and clinical studies have shown that elevated MGMT protein levels or lack of MGMT promoter methylation is associated with TMZ resistance in some, but not all, GBM tumors. In this study, the relationship between MGMT protein expression and tumor response to TMZ was evaluated in four GBM xenograft lines that had been established from patient specimens and maintained by serial subcutaneous passaging in nude mice. Three MGMT unmethylated tumors displayed elevated basal MGMT protein expression, but only two of these were resistant to TMZ therapy (tumors GBM43 and GBM44), while the other (GBM14) displayed a level of TMZ sensitivity that was similar in extent to that seen in a single MGMT hypermethylated line (GBM12). In tissue culture and animal studies, TMZ treatment resulted in robust and prolonged induction of MGMT expression in the resistant GBM43 and GBM44 xenograft lines, while MGMT induction was blunted and abbreviated in GBM14. Consistent with a functional significance of MGMT induction, treatment of GBM43 with a protracted low-dose TMZ regimen was significantly less effective than a shorter high-dose regimen, while survival for GBM14 was improved with the protracted dosing regimen. In conclusion, MGMT expression is dynamically regulated in some MGMT nonmethylated tumors, and in these tumors, protracted dosing regimens may not be effective.

AB - Temozolomide (TMZ)-based therapy is the standard of care for patients with glioblastoma multiforme (GBM), and resistance to this drug in GBM is modulated by the DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT). Expression of MGMT is silenced by promoter methylation in approximately half of GBM tumors, and clinical studies have shown that elevated MGMT protein levels or lack of MGMT promoter methylation is associated with TMZ resistance in some, but not all, GBM tumors. In this study, the relationship between MGMT protein expression and tumor response to TMZ was evaluated in four GBM xenograft lines that had been established from patient specimens and maintained by serial subcutaneous passaging in nude mice. Three MGMT unmethylated tumors displayed elevated basal MGMT protein expression, but only two of these were resistant to TMZ therapy (tumors GBM43 and GBM44), while the other (GBM14) displayed a level of TMZ sensitivity that was similar in extent to that seen in a single MGMT hypermethylated line (GBM12). In tissue culture and animal studies, TMZ treatment resulted in robust and prolonged induction of MGMT expression in the resistant GBM43 and GBM44 xenograft lines, while MGMT induction was blunted and abbreviated in GBM14. Consistent with a functional significance of MGMT induction, treatment of GBM43 with a protracted low-dose TMZ regimen was significantly less effective than a shorter high-dose regimen, while survival for GBM14 was improved with the protracted dosing regimen. In conclusion, MGMT expression is dynamically regulated in some MGMT nonmethylated tumors, and in these tumors, protracted dosing regimens may not be effective.

KW - Glioblastoma xenografts

KW - MGMT induction

KW - Promoter methylation

KW - Temozolomide

UR - http://www.scopus.com/inward/record.url?scp=67649610349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649610349&partnerID=8YFLogxK

U2 - 10.1215/15228517-2008-090

DO - 10.1215/15228517-2008-090

M3 - Article

VL - 11

SP - 281

EP - 291

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 3

ER -